B. Wells

1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

P. Lam, K. He, R. Knabb, 2006, Bioorganic & medicinal chemistry letters.

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.

P. Lam, K. He, R. Knabb, 2006, Bioorganic & medicinal chemistry letters.

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: optimization of the S4 ligand.

C. Dominguez, T. Maduskuie, R. Knabb, 2000, Bioorganic & medicinal chemistry letters.

(N-acyl-N-alkyl)glycyl borolysine analogs: A new class of potent thrombin inhibitors

M. Abelman, P. Weber, R. Knabb, 1996 .

Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).

P. Lam, R. Knabb, R. Alexander, 2003, Journal of medicinal chemistry.

Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.

P. Lam, K. He, R. Knabb, 2008, Bioorganic & medicinal chemistry letters.

Biochemical and crystallographic characterization of homologous non-peptidic thrombin inhibitors having alternate binding modes.

P. Weber, C. Kettner, C. Strickland, 1998, Acta crystallographica. Section D, Biological crystallography.